NEW YORK--(BUSINESS WIRE)--Oligomerix, Inc., a privately held company targeting tau oligomers for developing disease modifying therapeutics for Alzheimer’s disease (AD) and related neurodegenerative disorders, announced today the receipt of an award for a Direct-to-Phase-II Small Business Innovation Research (SBIR) grant for a two year program for a total of $1.5 M from the National Institutes of Health (NIH), National Institute on Aging (NIA).
This Direct-to-Phase II SBIR program is designed to advance the Company’s small molecule lead compounds inhibiting the formation of tau oligomers, the acutely toxic aggregates of tau that also play an important role in AD progression. Oligomerix will be working in close collaboration with Alzheimer’s expert Peter Davies, Ph.D., Director, Litwin-Zucker Center for Research on Alzheimer’s Disease, The Feinstein Institute for Medical Research, Northwell Health. The compounds will be tested in the human tau (htau) mouse model that was developed in the laboratory of Dr. Davies and best represents tau pathology in AD.
"Development of a disease-modifying therapy for AD patients is an urgent medical priority. We’re grateful for the NIH support and its scientific approval of our program targeting tau oligomers for drug discovery for AD. We are privileged to be working closely with Dr. Davies, a renowned leader in tau biology. This project aims to validate our drug discovery approach in vivo to enable selection of candidates for clinical development,” said James Moe, Ph.D., MBA, Oligomerix’s President and CEO, and principal investigator on the SBIR grant.
Oligomerix, Inc. is a biopharmaceutical company based in New York focused on the discovery and development of small molecule inhibitors targeting tau oligomers and associated biomarkers. The Company is seeking strategic partners and investors to help accelerate these exciting programs. For more information, visit www.oligomerix.com.
Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services.